Inventiva is focused on developing differentiated treatments for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), with a commitment to scientific excellence and patient urgency
Inventiva is focused on developing differentiated treatments for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), with a commitment to scientific excellence and patient urgency. Their lead product candidate, lanifibranor, is currently in clinical development and has received FDA Breakthrough Therapy Designation.
The top three firms on F4's Biotech & Life Sciences investor list.